Brucellosis is consistently ranked as the world’s most common and widespread zoonotic disease, meaning that it normally exists in animals but it can also infect humans. In livestock, it causes devastating production losses in low-...
Brucellosis is consistently ranked as the world’s most common and widespread zoonotic disease, meaning that it normally exists in animals but it can also infect humans. In livestock, it causes devastating production losses in low-income countries accounting in more than €3bn per year. In humans, there are 500,000 new cases annually requiring long-term hospital treatments.
Brucellosis is endemic in most Asia, Africa and LATAM and is prevalent in the EU Mediterranean regions. Also, outbreaks may take place anywhere in a global world with international trading, people travelling all around the world and potential threat of bioterrorism.
Since human vaccines are not available, the most rational approach for preventing human brucellosis is the control and eradication of infection in animals. Animal vaccines are an essential tool, but existing vaccines own some inconveniences, such as residual virulence, complex management systems and costly diagnostic techniques that are not appropriate for developing countries; in Europe, control programs are based in tests for animal check-ups and compensation to farmers for slaughter of the infected animals, with vaccination prohibited or highly restricted to areas with higher prevalence of Brucellosis. These inconveniences recommended the development of new candidate vaccines.
We are developing BGV1, a patented vaccine that has the potential of allowing, for the first time, mass vaccination of any animal at any time (including pregnant and lactating animals), which is a radical paradigm shift in Brucellosis control and eradication. It also simplifies existing vaccine management systems as it can be used without interfering standard diagnostic techniques. In our 5-year forecast, we estimate accumulated revenue and net profits of €58.29m and €15.13m, a conservative projection by just reaching 86.02m animals that represent only 3.92% of our TAM, generating 1.76bn economic benefits to our users.ver más
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
BRUCELLA GREEN VAC
La fabricación y comercialización de vacunas y métodos de diagnóstico veterinario. el desarrollo de productos biotecnológicos veterinarios.
Seleccionando "Aceptar todas las cookies" acepta el uso de cookies para ayudarnos a brindarle una mejor experiencia de usuario y para analizar el uso del sitio web. Al hacer clic en "Ajustar tus preferencias" puede elegir qué cookies permitir. Solo las cookies esenciales son necesarias para el correcto funcionamiento de nuestro sitio web y no se pueden rechazar.
Cookie settings
Nuestro sitio web almacena cuatro tipos de cookies. En cualquier momento puede elegir qué cookies acepta y cuáles rechaza. Puede obtener más información sobre qué son las cookies y qué tipos de cookies almacenamos en nuestra Política de cookies.
Son necesarias por razones técnicas. Sin ellas, este sitio web podría no funcionar correctamente.
Son necesarias para una funcionalidad específica en el sitio web. Sin ellos, algunas características pueden estar deshabilitadas.
Nos permite analizar el uso del sitio web y mejorar la experiencia del visitante.
Nos permite personalizar su experiencia y enviarle contenido y ofertas relevantes, en este sitio web y en otros sitios web.